Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Boric Acid→

Boric Acid Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
10043-35-3
Molecular formula
BH3O3
Molecular weight
61.84 g/mol
Drug class
Weak inorganic acidtopical antiseptic and antifungal ingredient in selected products
Mechanism of action
Exerts local antimicrobial effects through disruption of microbial enzyme activity, membrane function and intracellular pH balance. The exact mechanisms depend on organism, concentration and formulation; systemic exposure is toxic and not a therapeutic use.
Indications / reported uses
  • Selected topical antiseptic or antifungal uses in specific ophthalmic, otic or vaginal products where authorised; formulations and concentrations are route-specific and must not be interchanged
  • Not for ingestion or application to large areas of damaged skin; use only under applicable product authorisation

Sources: NLM MeSH — Boric acid · PubMed — Boric acid topical antimicrobial use · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Boric Acid Environmental Risk Assessment (ERA) (the Boric Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.